Dr. Pierce coming over to us was probably the singularly most important event of 2013. The man leaving A Huge name like Merck to come work for tiny little ONCS speaks volumes. Being a leader in the PD-1 field, Pierce knew the value that Immunopulse brought to the table. The small amount of stocks awarded in no-way explains his leaving Merck to come to us. Only one explanation, and one he's elaborated on before: He believes Immunopulse + anti-pd-1s will be the success story of current immunotherapy. Even if I didn't know all that I do about the two treatments, being who he is, i'd f#ckin take his word on it lol..
Immunpulse is opening the door to a giant part of the population for Anti-PD-1 treatment, which would have been excluded otherwise.
With these new additions to our pipeline, our market share will transcend skin cancer. Once people really wise up to the epic scope of our incoming treatments, sh#t will hit the fan.
With these new additions included, I peg fair valuation as of right now to be in the 3$ dollar range conservatively.
News 
Market Data 
Discover 
AI
